Sarepta’s Exondys 51 Q2 sales up 29%; shares up 3% after hours

Sarepta Therapeutics (NASDAQ:SRPT) Q2 results:

Exondys 51 sales: $94.7M (+29%).

Net loss: ($276.4M); loss/share: ($3.74).

FDA action date August 19 for Vyondys 53 (golodirsen). U.S. marketing application for casimersen about to be filed with an expected FDA action date in H1 2020.

Shares up 3% after hours.

Previously: Sarepta Therapeutics EPS beats by $0.42, beats on revenue(Aug. 7)

https://seekingalpha.com/news/3488822-sareptas-exondys-51-q2-sales-29-percent-shares-3-percent-hours